Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Neoplastic Syndromes, Hereditary

ClinicalTrials.gov lists 1,174 trials for Neoplastic Syndromes, Hereditary or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 104.

MeSH D009386 Neoplasms Neoplasm C04 C16 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 146 Phase 1/2 Phase 1/2 58 Phase 2 Phase 2 210 Phase 2/3 Phase 2/3 17 Phase 3 Phase 3 71 Phase 4 Phase 4 28 Not applicable Not applicable 291 Observational Observational 347 Phase 1 Phase 1 146 Phase 1/2 Phase 1/2 58 Phase 2 Phase 2 210 Phase 2/3 Phase 2/3 17 Phase 3 Phase 3 71 Phase 4 Phase 4 28 Not applicable Not applicable 291 Observational Observational 347

Trials per phase (log scale)

1 more section with rows

44 of the 1,174 trials are tagged with Neoplastic Syndromes, Hereditary itself; the rest are tagged with a narrower condition beneath it.

Get the Neoplastic Syndromes, Hereditary report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Neoplastic Syndromes, Hereditary trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 80

1990: 1 trials (Phase 2 1) 1992: 1 trials (Phase 2 1) 1993: 4 trials (Observational 2, Phase 3 1, Phase 2 1) 1994: 2 trials (Observational 1, Phase 1 1) 1995: 4 trials (Observational 2, Phase 3 1, Phase 2 1) 1996: 4 trials (Observational 2, Phase 3 1, Phase 2 1) 1997: 4 trials (Not applicable 1, Phase 2 1, Phase 1/2 1, Phase 1 1) 1998: 8 trials (Observational 3, Phase 3 1, Phase 2 2, Phase 1 2) 1999: 9 trials (Observational 3, Phase 3 3, Phase 2 1, Phase 1/2 1, Phase 1 1) 2000: 11 trials (Observational 3, Phase 3 1, Phase 2 4, Phase 1/2 2, Phase 1 1) 2001: 17 trials (Observational 4, Not applicable 1, Phase 3 1, Phase 2 6, Phase 1 5) 2002: 16 trials (Observational 5, Not applicable 1, Phase 4 2, Phase 3 1, Phase 2 4, Phase 1 3) 2003: 8 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 1, Phase 2 2, Phase 1/2 1) 2004: 17 trials (Observational 8, Not applicable 3, Phase 4 1, Phase 2/3 1, Phase 2 4) 2005: 23 trials (Observational 6, Not applicable 5, Phase 2 7, Phase 1/2 1, Phase 1 4) 2006: 39 trials (Observational 8, Not applicable 5, Phase 4 2, Phase 3 3, Phase 2/3 3, Phase 2 11, Phase 1/2 2, Phase 1 5) 2007: 31 trials (Observational 9, Not applicable 6, Phase 3 3, Phase 2 4, Phase 1/2 3, Phase 1 6) 2008: 27 trials (Observational 9, Not applicable 6, Phase 3 2, Phase 2 5, Phase 1/2 2, Phase 1 3) 2009: 41 trials (Observational 10, Not applicable 8, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 8, Phase 1 9) 2010: 47 trials (Observational 14, Not applicable 10, Phase 4 4, Phase 3 3, Phase 2 7, Phase 1/2 2, Phase 1 7) 2011: 31 trials (Observational 6, Not applicable 9, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 4) 2012: 50 trials (Observational 22, Not applicable 9, Phase 4 1, Phase 2/3 1, Phase 2 9, Phase 1/2 1, Phase 1 7) 2013: 30 trials (Observational 11, Not applicable 4, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 3) 2014: 43 trials (Observational 10, Not applicable 12, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 9, Phase 1/2 1, Phase 1 8) 2015: 53 trials (Observational 16, Not applicable 15, Phase 4 1, Phase 3 5, Phase 2 7, Phase 1/2 1, Phase 1 8) 2016: 44 trials (Observational 13, Not applicable 12, Phase 3 3, Phase 2/3 1, Phase 2 10, Phase 1/2 1, Phase 1 4) 2017: 72 trials (Observational 16, Not applicable 16, Phase 3 7, Phase 2 20, Phase 1/2 7, Phase 1 6) 2018: 62 trials (Observational 15, Not applicable 23, Phase 4 3, Phase 3 2, Phase 2 12, Phase 1 7) 2019: 52 trials (Observational 20, Not applicable 13, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 10, Phase 1/2 1, Phase 1 3) 2020: 58 trials (Observational 13, Not applicable 21, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 12, Phase 1/2 2, Phase 1 4) 2021: 80 trials (Observational 25, Not applicable 20, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 9, Phase 1/2 6, Phase 1 16) 2022: 60 trials (Observational 20, Not applicable 13, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 7, Phase 1/2 5, Phase 1 10) 2023: 46 trials (Observational 14, Not applicable 17, Phase 4 3, Phase 3 2, Phase 2 7, Phase 1/2 3) 2024: 47 trials (Observational 20, Not applicable 14, Phase 3 3, Phase 2 3, Phase 1/2 4, Phase 1 3) 2025: 63 trials (Observational 23, Not applicable 25, Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 9)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 50
2025 63
2024 47
2023 46
2022 60
2021 80
2020 58
2019 52
2018 62
2017 72

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 64 trials starting in 2026 and about 59 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 95 trials still running at the 2026-10-09 snapshot; registered median of 37 months across 685 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Neoplastic Syndromes, Hereditary trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 146
Phase 1/2 58
Phase 2 210
Phase 2/3 17
Phase 3 71
Phase 4 28
Not applicable 291
Observational 347
Expanded access 6

How many Neoplastic Syndromes, Hereditary trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 43
Recruiting 175
Enrolling by invitation 15
Active, not recruiting 85
Available 3

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Neoplastic Syndromes, Hereditary trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 104
Children's Oncology Group 30
Novartis Pharmaceuticals 21
Bayer 13
AstraZeneca 11

Which drugs are being tested for Neoplastic Syndromes, Hereditary? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
EVEROLIMUS 28
Selumetinib 23
Sirolimus 22
Cytoxan 16
Elinzanetant 11

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Vincristina 18
or carboplatin 17
Etoposid 15
Doxorubicine 14
Filgrastime (G-CSF) 12

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Neoplastic Syndromes, Hereditary trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 409 24
COVID-19 pneumonia 204 4
Angina unstable 202 2
Angina pectoris 193 6
Coronary artery disease 182 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Neoplastic Syndromes, Hereditary? (95)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer. The New England journal of medicine 2025 Yes
Reproductive decision-making and pregnancy in germline <i>CDH1</i> variant carriers. Journal of medical genetics 2025 Yes
SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR <i>BRAF</i>V600E-mutant mCRC. Future oncology (London, England) 2024 Yes
Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial. BMC cancer 2024 Yes
Clinical Utility of Genomic Sequencing for Hereditary Cancer Syndromes: An Observational Cohort Study. JCO precision oncology 2024 Yes

Showing 5 of 95 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (14)

MeSH descendants one level down with at least one trial, most trials first.

+4 more sub-conditions

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages